 - Completion of the Week 48 open-label extension OLE visit or any post Week 48 OLE visits in Gilead-sponsored study GS US 236-0128, or Completion of the Week 96 visit or any post Week 96 visits in Gilead-sponsored study GS US-292-0109 or completion of the Week 144 visit or any post Week 144 visits in Gilead sponsored studies GS-US-292-0104 or GS-US-292-0111. 